MACLEODS PHARMS
GenericsMACLEODS PHARMS is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
MACLEODS PHARMS's Key Drugs
MACLEODS PHARMS's core commercial portfolio centers on OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, SACUBITRIL AND VALSARTAN, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Hypertension
Hypertension
Heart Failure
Overactive Bladder
Hypertension
MACLEODS PHARMS's Recent FDA Approvals
MACLEODS PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
MACLEODS PHARMS's Therapeutic Areas
MACLEODS PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MACLEODS PHARMS's Top Competitors
MACLEODS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MACLEODS PHARMS Pipeline Snapshot
Active clinical trials for MACLEODS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (14)
Discontinued (10)
Company Info
- First Approval
- 2012-01-12
- Latest
- 2026-08-31
- Applications
- 179